Incyte Corporation (NASDAQ: INCY) has recently seen a notable increase in market attention, as shares climbed by 4.5% after the latest announcement showcasing positive initial results for their innovative antibody, INCA033989. The study results reveal that the treatment is especially effective for high-risk patients diagnosed with CALR-mutant essential thrombocythemia, showing significant improvement in 86% of cases, with 82% achieving a complete remission rate. Impressively, no dose-limiting toxicities were reported, highlighting the treatment's potential safety and efficacy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.